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ABSTRACT
Known susceptibility genes to atopy and asthma have been identified by linkage or associations with clinical
phenotypes, including total serum IgE levels. IgE-mediated sensitivity reactions require a high-affinity IgE re-
ceptor (FcεRI), which immobilizes the immunoglobulin on the surface of the effector cells, mostly mast cells and
basophils. In this mini-review, recent findings are presented on genetic variation of this receptor, as related to
atopy. Transcription of FCER1A gene encoding the receptor α subunit can be initiated from two separate pro-
moters, the proximal one and the distal one, which results in a transcript containing two novel untranslated ex-
ons (1A, 2A). Our knowledge on the role of this mechanism in allergic diseases is still at an infancy stage.
Within regulatory elements of FCER1A some common single nucleotide polymorphisms have functional asso-
ciations, which were recently reported and replicated in different ethnical groups. Interestingly, these associa-
tions do not confer susceptibility to allergic diseases, but rather modulate serum concentrations of IgE. Similarly
to the previously investigated β subunit of the receptor, FCER1A is a good candidate for a quantitative trait lo-
cus (QTL) in allergic diseases, and appears to participate in the systemic regulation of IgE levels.
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INTRODUCTION
Allergic diseases, such as asthma or atopic dermati-
tis, run in families suggesting the presence of a com-
mon genetic predisposition. Genomic studies are fre-
quently conducted in asthma and other allergy-
associated diseases, with the aim of developing a bet-
ter understanding of underlying processes.1,2 Many
genetic loci and defined genes have been associated
with the etiology of allergic disorders.1 One of the
pioneering discoveries in allergy-related genetics was
the association between atopy and the 11q13 genetic
locus.1,3-5 Subsequent research revealed that the 11q
13 genetic locus contains among others the FCER1B
gene, encoding for the high-affinity IgE receptor
(FcεRI) β chain (FcεRIβ).4,5
HIGH-AFFINITY IgE RECEPTOR STRUC-
TURE AND FUNCTION
FcεRI is expressed mainly on the surface of mast
cells, basophils, dendritic cells, Langerhans cells and
monocytes.6-9 Binding of the polyvalent antigens to
specific IgE molecules occupying FcεRI on basophils
and mast cell membranes is an initial step in the se-
quence of the atopic reaction.7-13 On these cells,
FcεRI has a heterotetrameric form and consists of an
FcεRIβ and α subunit (FcεRIα), and two γ chains
(FcεRIγ), that build the αβγ2 complex (Fig. 1).7,8,11,14
In humans but not in mice, the trimeric molecule of
the receptor also exists, with one FcεRIα and two
FcεRIγ chains comprising the αγ2 complex.7,8,14
FcεRIα is the receptor subunit responsible for the
IgE binding. It has two extracellular immunoglobulin-
like domains, a transmembrane hydrophobic region,
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Fig. 1 High-afinity  IgE  receptor  (FcεRI)  tetrameric 
structure. ITAM denotes immunoreceptor tyrosin-based acti-











and a positively-charged short cytoplasmic tail. (Fig.
1).7,10-12,14 The remaining FcεRI subunits, arranged in
a βγ2 complex, are responsible for signal transduc-
tion across the cell membrane. FcεRIβ has four trans-
membrane domains and two cytoplasmic tails (Fig.
1). FcεRIγ has a single transmembrane domain and a
cytoplasmatic tail. Intracellular components of FcεRI
undergo protein phosphorylation upon signaling at
the characteristic immunoreceptor tyrosine-based ac-
tivation motifs (ITAM) (Fig. 1).7,8,13,14 IgE is pro-
duced by B cells in the spleen, lymph nodes, and lo-
cally. Recently demonstrated local tissues, e.g. sinus
mucosa, may be populated by IgE producing cells at
a much higher ratio following allergen exposure.15
Despite common beliefs, stability of circulating IgE is
similar to IgG. There is only binding to FcεRI, which
increases the half-live of this immunoglobulin, due to
a high avidity and low dissociation constant of such a
complex.16
GENETICS OF HIGH-AFFINITY IgE RECEP-
TOR SUBUNITS
Genetic association studies on FCER1B variability
were animated by the cloning of the gene at locus
11q13,3-5 formerly linked with allergy-related disor-
ders or atopy measures, such as bronchial hyperreac-
tivity. Many reports published during the last decade
dealt with the association between FCER1B gene
polymorphic variants and allergic disorders. These
findings were in general replicated within several eth-
nic groups, encompassing Caucasians, Japanese, Chi-
nese and South Africa Blacks. Variants of the
FCER1B gene have been associated with asthma,17,18
atopy,19,20 bronchial hyperreactivity,19 serum IgE lev-
els17 and atopic dermatitis.5
Likewise, the FcεRIγ encoding gene (FCER1G)
was screened for the presence of genetic variants. In
the study on systemic lupus erythematosus, the gene
turned out to be conservative in its coding sequence
both within patients and healthy controls.21
Genetic variability of the gene encoding for FcεRIα
(FCER1A) was previously out of the focus of studies
and until quite recently only two relevant papers were
published.8,22,23 This is surprisingly in contrast with
many investigations on structural and functional prop-
erties of the FCER1A gene.24-33
STRUCTURE AND FUNCTION OF THE
GENE ENCODING FOR HIGH-AFFINITY IgE
RECEPTORα SUBUNIT (FCER1A)
FCER1A gene is localized on chromosome 1q23.
Originally, FCER1A gene had been described as con-
sisting on five exons (Ex1―5), and its expression be-
ing regulated by a single promoter(Fig. 2).24-26 By
FCER1A transcripts studies, presence of two addi-
tional FCER1A exons remotely localized at 12,000
bps (Ex2A) and 18,000 bps (Ex1A) upstream to the
coding sequence was discovered (Fig. 2).28,32 In-
itially, the Ex1A sequence of 9 nucleotides was deter-
mined, however, it was still expected to extend fur-
ther upstream.28 Indeed, subsequent studies revealed
the Ex1A to be much longer (335 bp).32 Two alterna-
tive FCER1A transcription start sites were also identi-
fied, both within the Ex1A neighbourhood.32 This
was accompanied by a discovery of a supplementary
(‘distal’) promoter region.32 Due to this alternative
FCER1A gene promoter, the one formerly known and
localized just upstream of translated Ex1 was re-
named the ‘proximal’ one (Fig. 2). Thus, FCER1A
gene expression is controlled by two different pro-
moter regions.29,31-33 In mast cells, under normal con-
ditions, FCER1A gene transcription is regulated by
the proximal promoter;29,31-33 this requires some tran-
scription factors, namely: GATA-1 and PU.1, as well
as YY1 and Elf-1.27,29-31,33 In mast cells, eosinophils
and monocytes FcεRI expression is enhanced by
interleukin-4 (IL-4). Effects of this cytokine on FCER
1A gene transcription seem I, however, not to be me-
diated by the proximal promoter but rather by the hu-
man specific distal one.32,33 The distal promoter is
negatively regulated by a limited set of transcription
factors, such as Elf-1, PU.1 and YY1.32,33 Therefore,
both promoters vary not only in their response to IL-
4, but also their regulatory mechanisms are differ-
ent.27,29-33 The increased FcεRIα expression in aller-
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Fig. 2 Schematic representation of the gene encoding for 
high-afinity IgE receptor α subunit (FCER1A) and its poly-
morphisms we studied.
－18674/－18675 delAA
－18483 A > C
Ex1A Ex2A Ex1Ex2 Ex3 Ex4 Ex5
－12663 A > G
－344 C > T
－95 T > C
DISTAL PROMOTER PROXIMAL PROMOTER
gic diseases patients, due to both FCER1A gene pro-
moter activity, represent an attractive therapeutic tar-
get.33,34
FCER1A GENETIC VARIABILITY AND TO-
TAL SERUM IgE LEVELS
In the study by Shikanai et al.,23 mutational screening
of the proximal promoter and five protein coding
FCER1A gene exons (Ex1―5) was performed on Cau-
casian and Afro-American asthmatics and healthy
controls. No mutations causing an amino acid change
were detected in Ex1―5.23 However, in the regulatory
region 5’ to the Ex1 (proximal promoter) three poly-
morphisms were found, i.e. −770 A > C, −664 G > A
and −335 C > T, the last one being the most fre-
quent.23 No significant differences in genotype distri-
butions and allelic frequencies were found between
asthmatics and healthy controls.23 Some interracial
differences were detected in allelic frequences. The
frequency of the −770 A > C FCER1A polymorphism
varied between Caucasian and Afro-American asth-
matics; −335 C > T allelic frequencies showed interra-
cial differences both in patients with asthma and in
healthy controls.23 Shikanai et al. found also a greater
proportion of CC homozygotes of −335 C > T poly-
morphism in Caucasian asthmatic patients with total
serum IgE levels in the lower quartile, contrasted to
those with higher IgE concentrations.23
In the Japanese study Hasegawa et al.22 screened
for FCER1A variability in patients with atopic derma-
titis and in a healthy control group. They found an-
other polymorphism of the region, named −66 T > C
within the FCER1A regulatory sequence of the proxi-
mal promoter.22 A difference in of −66 T > C FCER1A
genotypes frequencies between healthy non-allergic
subjects and patients with atopic dermatitis sug-
gested a possible association of the gene with predis-
position to this allergic condition. Further molecular
experiments showed that −66 T > C FCER1A gene
polymorphism affects binding of transcriptional factor
GATA-1 to the proximal promoter and, thus, a tran-
scriptional activity of the gene.22
In a study recently completed in Poland, we used a
similar mutational screening strategy on the proximal
promoter region of FCER1A, examining the allergic
subjects with asthma or urticaria, and Polish
population-based age- and sex-matched controls.35
We confirmed the presence of the two common poly-
morphisms, the one previously reported by Shikanai
et al.23 (−335 C > T) and the other reported by Hase-
gawa et al.22 (−66 T > C). In order to unify the nomen-
clature, these polymorphisms are currently referred
to as −344 C > T and −95 T > C, using a translation
start nucleotide as the first one.22,23,35 Both genetic
variations were in complete linkage disequilibrium.
No differences were found in genotypes distributions
between the groups of patients and healthy controls.
Similarly, a haplotype analysis did not reveal any ge-
netic associations with allergic diseases.35 Interest-
ingly, −344 TT genotype was associated with higher
total serum IgE levels in allergic patients but not in
controls.35 This observation indirectly corroborated
with previous results; e.g. Shikanai et al. described a
more frequent −344 CC genotype in asthmatic pa-
tients with lower serum IgE levels.23,35
This genetic association between −344 C > T poly-
morphism and total serum IgE levels was replicated
by Bae et al.36 In a study on the association between
−344 C > T or −95 T > C polymorphisms and aspirin-
induced urticaria, they found the carriers of the −344
T allele to have higher total serum IgE concentra-
tions than subjects with the CC genotype.36 More-
over, functional studies of the −344 C > T polymor-
phism suggested an altered proximal promoter tran-
scriptional activity possibly related to binding of the
transcription factor MAZ.36
In an extended study, in which we continued muta-
tional screening of distal FCER1A gene regions, in-
cluding Ex1A and the distal promoter no variants
were encountered in the distal promoter.37 However,
two novel common polymorphisms were found in Ex
1A (−18483 A > C, −18674－18675 delAA). All the
four FCER1A polymorphisms (−344 C > T, −95 T > C,
−18483A > C and −18674－18675delAA) were in
tight linkage disequilibrium. Again, no genotypes or
reconstructed haplotypes frequencies differed be-
tween the subject groups of allergic patients and
healthy controls.37 The association between the −344
TT genotype and higher serum IgE levels was recon-
firmed in a group composed of allergic patients suf-
fering from asthma, urticaria, persistent allergic rhini-
tis or simple pollinosis.37 This relationship remained
significant using QTL analysis contrasting −344C > T
genotypes against the other three polymorphisms. In-
terestingly enough, −18483 CC homozygotes also
showed a statistical tendency toward higher total se-
rum IgE levels in allergic patients.37 However, in a
subgroup of asthmatics only, both −18483 CC and −
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344 TT genotypes were highly significantly associ-
ated with higher total serum IgE levels.37
No common mutations in FCER1A gene Ex2A
were found, however, a rare single nucleotide poly-
morphism (−12663 A > G) was located several nucleo-
tides upstream.38
PERSPECTIVES FOR FCER1A GENE VARI-
ABILITY STUDIES: FcεRI-TARGETTED AN-
TIALLERGIC DRUGS
IgE increases FcεRI expression on the cell surface by
preventing its degradation8,39,40 and serum IgE levels
correlate with FcεRI expression on different cell
types.9,41 Therefore, the presence of a hypothetic
positive feedback loop involving IgE upregulation of
FcεRI on basophils and mast cells, greater IL-4 secre-
tion induced by upregulated FcεRI, and higher IgE
production resulting from IL-4-dependent B-cell
switch for IgE synthesis was proposed.8 FcεRI pre-
sent on basophils and mastocytes might also affect
IgE levels by increasing the plasma half-life of the im-
munoglobulin.16
Our knowledge on FcεRI function and its relation
with IgE levels is in a large part derived from omali-
zumab studies. Anti-IgE therapy effectively down-
regulates FcεRI expression on mast cells,42 baso-
phils,43,44 dendritic cells45 and monocytes.46 This fur-
ther mediates cellular and clinical omalizumab ef-
fects. A similar response, though tested only in ani-
mals, was obtained by a vaccination against an IgE
specific CH3 domain, which is responsible for the im-
munoglobulin binding to FcεRI.16 It might be also
speculated, that targeting the regulatory regions of
FCER1A gene using recently discovered strategies,
e.g. interfering RNA molecules, could bring similar
effects.33,34 FCER1A gene variants, by their altered
transcriptional activities, offer a natural model for
studying relations between serum IgE levels and
clinical course of the disease. The role of FCER1A
variants in FcεRI cellular expression seems especially
important on antigen presenting cells, because they
lack expression of the FcεRIβ subunit in hu-
mans.7,47,48
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